| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/CXO.12472 |
| P698 | PubMed publication ID | 27701774 |
| P2093 | author name string | Danielle L Weiler | |
| P2860 | cites work | Orbital radiation therapy for Graves' ophthalmopathy: measuring clinical efficacy and impact | Q38228271 |
| Orbital fat decompression for thyroid eye disease: retrospective case review and criteria for optimal case selection | Q38246849 | ||
| Endoscopic medial orbital fat decompression for proptosis in type 1 graves orbitopathy | Q38275482 | ||
| Current trends in the management of thyroid eye disease | Q38591521 | ||
| A 2011 survey of clinical practice patterns in the management of Graves' disease | Q39540741 | ||
| Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. | Q40812821 | ||
| Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression | Q42925094 | ||
| Exophthalmos of patients with Graves' disease in Chinese of Taiwan | Q44008257 | ||
| Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment | Q45368044 | ||
| Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series | Q46965301 | ||
| Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy. | Q51353676 | ||
| Determination of the normal range of exophthalmometric values for black and white adults. | Q53907750 | ||
| Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management | Q26782424 | ||
| Acute thyroid eye disease (TED): principles of medical and surgical management | Q26827429 | ||
| The evaluation and treatment of graves ophthalmopathy | Q26862144 | ||
| Selenium and the course of mild Graves' orbitopathy | Q28238021 | ||
| Graves' ophthalmopathy | Q28274196 | ||
| Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach | Q33647383 | ||
| Successful treatment of diplopia with prism improves health-related quality of life | Q33700230 | ||
| Radiotherapy for thyroid-associated orbitopathy | Q33806019 | ||
| Smoking and thyroid disorders--a meta-analysis | Q33845621 | ||
| Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. | Q34010116 | ||
| Graves ophthalmopathy | Q34392878 | ||
| Diagnosis and classification of Graves' disease | Q34397821 | ||
| Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. | Q35055076 | ||
| Randomized controlled trial of rituximab in patients with Graves' orbitopathy | Q35055124 | ||
| Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism | Q35837670 | ||
| Risk factors for development or deterioration of Graves' ophthalmopathy | Q35975724 | ||
| The pathophysiology of thyroid eye disease: implications for immunotherapy. | Q36439938 | ||
| Cigarette smoking and thyroid eye disease: a systematic review | Q36596473 | ||
| VISA Classification for Graves orbitopathy | Q36598248 | ||
| The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy | Q36811289 | ||
| Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology | Q37033302 | ||
| Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy | Q37110191 | ||
| Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity | Q37829150 | ||
| Evaluating Graves' orbitopathy | Q38013209 | ||
| Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy | Q38013216 | ||
| Quality of life in Graves' ophthalmopathy | Q38013218 | ||
| Prevention of Graves' ophthalmopathy | Q38013219 | ||
| Orbital radiotherapy for thyroid eye disease | Q38021342 | ||
| Diagnosis and management of Graves disease: a global overview | Q38152621 | ||
| Effect of orbital decompression on diplopia in thyroid-related orbitopathy | Q38183690 | ||
| The pathophysiology of thyroid eye disease. | Q38211349 | ||
| Thyroid eye disease: therapy in the active phase | Q38211350 | ||
| Thyroid eye disease for the primary care physician. | Q38218334 | ||
| P433 | issue | 1 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 20-25 | |
| P577 | publication date | 2016-10-04 | |
| P1433 | published in | Clinical and Experimental Optometry | Q15767014 |
| P1476 | title | Thyroid eye disease: a review | |
| P478 | volume | 100 |
| Q92994581 | A Novel Method of CT Exophthalmometry in Patients With Thyroid Eye Disease |
| Q64117967 | Assessment of lacrimal glands in thyroid eye disease with diffusion-weighted magnetic resonance imaging |
| Q64285170 | Bioinformatic Analysis Identifies Potentially Key Differentially Expressed Genes and Pathways in Orbital Adipose Tissues of Patients with Thyroid Eye Disease |
| Q94554835 | Etiologies of Proptosis: A review |
| Q47323119 | Measurement of Orbital Biomechanical Properties in Patients with Thyroid Orbitopathy Using the Dynamic Scheimpflug Analyzer (Corvis ST). |
| Q58767198 | Orbital decompression surgery for the treatment of Graves' ophthalmopathy: comparison of different techniques and long-term results |
| Q92307656 | The Cerebellum Posterior Lobe Associates with the Exophthalmos of Primary Hyperthyroidism: A Resting-State fMRI Study |
| Q41665052 | Treatment of Graves' ophthalmopathy with an in-house Phosphorus-32 source: Initial clinical observations |
| Q41439533 | Variants of Interleukin-22 Gene Confer Predisposition to Autoimmune Thyroid Disease. |
Search more.